Section of Emergency Medicine and Cardiology, Department of Internal Medicine, Livorno Hospital, Livorno, Italy.
Clin Cardiol. 2010 Feb;33(2):E65-7. doi: 10.1002/clc.20546.
Type II heparin-induced thrombocytopenia (HIT) is a potentially severe adverse effect of heparin treatment triggered by an immune response. Although most cases occur in patients receiving unfractioned heparin, HIT can also arise after low-molecular-weight heparin (LMWH). We report a case of HIT in a postoperative orthopedic 75-year-old woman in treatment with LMWH (nadroparin) complicated by pulmonary embolism and treated successfully with recombinant hirudin. Early recognition and proper treatment are fundamental for the management of this life-threatening disorder.
II 型肝素诱导的血小板减少症(HIT)是肝素治疗引发的一种潜在严重的不良反应,由免疫反应触发。尽管大多数病例发生在接受未分级肝素的患者中,但 HIT 也可在低分子肝素(LMWH)治疗后出现。我们报告了一例 LMWH(那屈肝素)治疗的骨科术后 75 岁女性的 HIT 病例,该患者并发肺栓塞,并成功接受重组水蛭素治疗。早期识别和适当治疗对于这种危及生命的疾病的管理至关重要。